Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.
Seres Therapeutics (NASDAQ: MCRB), un'azienda leader nel campo dei biofarmaci vivi, ha programmato la conferenza telefonica per la presentazione dei risultati finanziari del secondo trimestre 2025 e gli aggiornamenti aziendali per il 6 agosto 2025 alle 8:30 ET.
L'azienda offrir脿 sia una conferenza telefonica che una trasmissione audio in diretta via web. Gli investitori potranno partecipare chiamando il numero 800-715-9871 (nazionale) o 646-307-1963 (internazionale) con ID conferenza 3641971. La trasmissione sar脿 disponibile nella sezione "Investitori e Notizie" del sito di Seres e rester脿 archiviata per circa 21 giorni.
Seres Therapeutics (NASDAQ: MCRB), una empresa l铆der en biof谩rmacos vivos, ha programado su llamada de conferencia para los resultados financieros del segundo trimestre de 2025 y actualizaciones comerciales para el 6 de agosto de 2025 a las 8:30 a.m. ET.
La compa帽铆a ofrecer谩 tanto una llamada de conferencia como una transmisi贸n de audio en vivo por internet. Los inversores pueden acceder a la llamada marcando 800-715-9871 (nacional) o 646-307-1963 (internacional) con el ID de conferencia 3641971. La transmisi贸n estar谩 disponible en la secci贸n "Inversores y Noticias" del sitio web de Seres y permanecer谩 archivada aproximadamente 21 d铆as.
Seres Therapeutics (NASDAQ: MCRB)電� 靹犽弰鞝侅澑 靸濎泊 旃橂鞝� 旮办梾鞙茧靹� 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚� 靷梾 鞐呺嵃鞚错姼 旎嵓霟办姢 旖滌潉 2025雲� 8鞗� 6鞚� 鞓れ爠 8鞁� 30攵�(霃欕秬鞁滉皠)鞐� 鞓堨爼頄堨姷雼堧嫟.
須岇偓電� 旎嵓霟办姢 旖滉臣 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 氇憪 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 甑偞: 800-715-9871, 甑牅: 646-307-1963氩堨溂搿� 旎嵓霟办姢 ID 3641971鞚� 鞛呺牓頃橃棳 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 鞗轨簮鞀ろ姼電� Seres 鞗轨偓鞚错姼鞚� "韴瀽鞛� 氚� 雺挫姢" 靹轨厴鞐愳劀 鞝滉车霅橂┌ 鞎� 21鞚缄皠 鞎勳勾鞚措笇霅╇媹雼�.
Seres Therapeutics (NASDAQ : MCRB), une entreprise leader dans le domaine des bioth茅rapies vivantes, a programm茅 sa conf茅rence t茅l茅phonique sur les r茅sultats financiers du deuxi猫me trimestre 2025 et les mises 脿 jour commerciales pour le 6 ao没t 2025 脿 8h30 ET.
L'entreprise proposera 脿 la fois une conf茅rence t茅l茅phonique et une diffusion audio en direct sur le web. Les investisseurs peuvent acc茅der 脿 l'appel en composant le 800-715-9871 (domestique) ou le 646-307-1963 (international) avec l'ID de conf茅rence 3641971. La diffusion sera disponible dans la section "Investisseurs et Actualit茅s" du site Seres et restera archiv茅e pendant environ 21 jours.
Seres Therapeutics (NASDAQ: MCRB), ein f眉hrendes Unternehmen im Bereich lebender Biotherapeutika, hat seine Telefonkonferenz zu den Finanzergebnissen und Gesch盲ftsupdates f眉r das zweite Quartal 2025 f眉r den 6. August 2025 um 8:30 Uhr ET angesetzt.
Das Unternehmen wird sowohl eine Telefonkonferenz als auch einen Live-Audio-Webcast anbieten. Investoren k枚nnen die Telefonkonferenz unter 800-715-9871 (national) oder 646-307-1963 (international) mit der Konferenz-ID 3641971 erreichen. Der Webcast wird im Bereich "Investoren und Nachrichten" auf der Seres-Website verf眉gbar sein und etwa 21 Tage archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc.鈥�(Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the 鈥淚nvestors and News鈥� section of the Seres website at聽www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc.聽(Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST鈩�, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestl茅 Health Science in聽September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.聽For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:鈥�
Carlo Tanzi, Ph.D.
Kendall Investor Relations
FAQ
When will Seres Therapeutics (MCRB) report Q2 2025 earnings?
How can investors access the Seres Therapeutics Q2 2025 earnings call?
How long will the MCRB Q2 2025 earnings webcast replay be available?
What topics will be covered in Seres Therapeutics' Q2 2025 conference call?
